Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Study ID
- NCT05599256
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Transplant-Related Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 16 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib — DRUGModel-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po. Model-predicted low risk: regular aGVHD prophylactic regimens.
Study Details
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.
Key Dates
- Start date
- Feb 9, 2023
- Status verified
- Mar 2024
- Primary completion
- Oct 7, 2024
- Completion
- Dec 1, 2025
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: The group of daGOAT model preventionModel-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po. Model-predicted low risk: regular aGVHD prophylactic regimens.
Primary Outcome Measure
Severe aGVHD during 100 days after transplantation according to the MAGIC criteria [ Time Frame: 100 days after transplantation ]
Central Contacts
- Xueou Liu, PhD022-23909051
Related Studies
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsPHASE2 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver TransplantRecruiting · University of Chicago · Chicago, Illinois